<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="817">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372004</url>
  </required_header>
  <id_info>
    <org_study_id>TCAI_CATCH COVID-19</org_study_id>
    <nct_id>NCT04372004</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)</brief_title>
  <acronym>CATCH COVID-19</acronym>
  <official_title>Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Cardiac Arrhythmia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Cardiac Arrhythmia Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the efficacy of detection of COVID-19 infection using the
      serology test in blood sample and the PCR-based test in the nasopharyngeal (NP) and sputum
      sample. Furthermore, it aims to evaluate the temporal trend of appearance of IgM and IgG in
      blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that viral-RNA test using sputum will be equally efficient as
      the test performed in NP swab. Moreover, the serology test and the PCR-based test will be
      comparable in efficacy for detection of infection
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject will be tested using 3 different samples on two testing platforms (serology and viral-RNA detection)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>detection of viral infection using serology and viral-RNA detection kits</measure>
    <time_frame>1 day</time_frame>
    <description>Detection of viral infection in the two test platforms using 3 specimen (blood, nasal swab and sputum) from the same subject, in detecting COVID-19 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temporal trend of antibodies in blood</measure>
    <time_frame>1 month</time_frame>
    <description>Temporal trend of the IgM and IgG production in response to the infection by conducting serial serology tests at bi-weekly interval</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Viral RNA test using nasopharyngeal swab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Viral RNA test using sputum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Serology test using blood</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>diagnostic tests for COVID-19 infection</intervention_name>
    <description>Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA</description>
    <arm_group_label>Serology test using blood</arm_group_label>
    <arm_group_label>Viral RNA test using nasopharyngeal swab</arm_group_label>
    <arm_group_label>Viral RNA test using sputum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Male or female over 18 years of age at the time of enrollment

               -  Current symptoms of COVID-19 ; fever alone or fever and at least one of the
                  following symptoms need to be present

                    -  Dry cough

                    -  Sore throat

                    -  Shortness of breath

                    -  Chills

                    -  Muscle pain

                    -  Headache

                    -  New loss of taste or smell

                    -  Chills with repeated shaking

        Exclusion Criteria:

          -  • Unwilling to provide informed consent

               -  Unwilling to undergo bi-weekly serological test during the 1-month enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MITRA Mohanty, MD</last_name>
    <phone>5127842651</phone>
    <email>mitra1989@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Cardinal, RN MBA</last_name>
    <phone>512) 807-3150</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitra Mohanty, MD</last_name>
      <phone>512-544-8186</phone>
      <email>mitra1989@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Angel Mayedo, MD</last_name>
      <phone>5125447254</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Cardiac Arrhythmia Research Foundation</investigator_affiliation>
    <investigator_full_name>Andrea Natale</investigator_full_name>
    <investigator_title>Executive Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

